Charged pion form factor between Q^2=0.60 and 2.45 GeV^2. II. Determination of, and results for, the pion form factor

The charged pion form factor, Fpi(Q^2), is an important quantity which can be used to advance our knowledge of hadronic structure. However, the extraction of Fpi from data requires a model of the 1H(e,e'pi+)n reaction, and thus is inherently model dependent. Therefore, a detailed description of the extraction of the charged pion form factor from electroproduction data obtained recently at Jefferson Lab is presented, with particular focus given to the dominant uncertainties in this procedure. Results for Fpi are presented for Q^2=0.60-2.45 GeV^2. Above Q^2=1.5 GeV^2, the Fpi values are systematically below the monopole parameterization that describes the low Q^2 data used to determine the pion charge radius. The pion form factor can be calculated in a wide variety of theoretical approaches, and the experimental results are compared to a number of calculations. This comparison is helpful in understanding the role of soft versus hard contributions to hadronic structure in the intermediate Q^2 regime.Comment: 18 pages, 11 figure

The Q2Q^2-dependence of the generalised Gerasimov-Drell-Hearn integral for the deuteron, proton and neutron

The Gerasimov-Drell-Hearn (GDH) sum rule connects the anomalous contribution to the magnetic moment of the target nucleus with an energy-weighted integral of the difference of the helicity-dependent photoabsorption cross sections. The data collected by HERMES with a deuterium target are presented together with a re-analysis of previous measurements on the proton. This provides a measurement of the generalised GDH integral covering simultaneously the nucleon-resonance and the deep inelastic scattering regions. The contribution of the nucleon-resonance region is seen to decrease rapidly with increasing $Q^2$. The DIS contribution is sizeable over the full measured range, even down to the lowest measured $Q^2$. As expected, at higher $Q^2$ the data are found to be in agreement with previous measurements of the first moment of $g_1$. From data on the deuteron and proton, the GDH integral for the neutron has been derived and the proton--neutron difference evaluated. This difference is found to satisfy the fundamental Bjorken sum rule at $Q^2 = 5$ GeV$^2$.Comment: 12 pages, 10 figure

Quark fragmentation to π±\pi^{\pm}, π0\pi^{0}, K±K^{\pm}, pp and pˉ\bar{p} in the nuclear environment

The influence of the nuclear medium on lepto-production of hadrons was studied in the HERMES experiment at DESY in semi-inclusive deep-inelastic scattering of 27.6 GeV positrons off deuterium, nitrogen and krypton targets. The differential multiplicity for krypton relative to that of deuterium has been measured for the first time for various identified hadrons ($\pi^+$, $\pi^-$, $\pi^0$, $K^+$, $K^-$, $p$ and $\bar{p}$) as a function of the virtual photon energy $\nu$, the fraction $z$ of this energy transferred to the hadron, and the hadron transverse momentum squared $p_t^2$. The multiplicity ratio is strongly reduced in the nuclear medium at low $\nu$ and high $z$, with significant differences among the various hadrons. The distribution of the hadron transverse momentum is broadened towards high $p_t^2$ in the nuclear medium, in a manner resembling the Cronin effect previously observed in collisions of heavy ions and protons with nuclei.Comment: 8 pages, 5 figure

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Clinical value of anaerobic blood culture: a retrospective analysis of positive patient episodes

Aim—To investigate the clinical value of anaerobic blood culture. Methods—Blood culture bottles (n = 25 185) submitted for culture over a two year period were reviewed. Results—The bottles yielded 1992 positive patient episodes, a positive rate of 14.4/1000 hospital admissions. Significantly more isolations were obtained from aerobic than from anaerobic bottles. Twelve of the 38 anaerobic episodes were detected in aerobic bottles. Clinical management was influenced in one of 24 patients whose cultures yielded anaerobes from anaerobic bottles only. For a further six patients it was unlikely that the result had any effect on clinical management. Conclusions—If aerobic bottles were substituted for the anaerobic bottles, detection of positive patient episodes would increase by at least 6%. A higher yield would be achieved by using two aerobic bottles for routine culture and using anaerobic bottles only for patients where anaerobic culture may influence clinical management. Key Words: blood culture • anaerobes • BacT/Aler

Reply to “Marine abundance and its prehistoric past in the Baltic”

In response to the comment by Hausmann et al.1 we highlight here that a number of the key criticisms of Lewis et al.2 are either misinterpretations of our paper or are speculative, requiring rigorous testing via empirical data (and subsequently are topics for further research). We would, therefore, like to take the opportunity to clarify these points, so that others do not misinterpret our study2 in the same way. Hausmann et al.1 provide no physical evidence or data that rebuke our hypothesis, and therefore in the spirit of critical scientific discussion and endeavour, we challenge them (or others) to disprove our hypothesis through high-quality data, and hope that our original paper2 and this further discussion stimulate such work. The criticisms expressed by Hausmann et al. largely focus on the use of a summed probability distribution 14C curve based on oysters as a proxy for shell midden abundance, yet this is only a supportive dataset within the broader theme of this study, and we certainly welcome future research into improving how we quantify shell midden abundance and marine resource intensification in past cultures and societies. However, we highlight that the criticisms of this 14C oyster-derived dataset by Hausmann et al.1 does not detract from the key point of this study, that population increased during periods of increased marine productivity (demonstrated by sediment pigment and other proxy data) and hence increased marine resource availability, when humans predominately consumed a marine-based diet3. Below we respond to the specific points raised by Hausmann et al.1. </p

Serological profiling of the EBV immune response in Chronic Fatigue Syndrome using a peptide microarray.

Background: Epstein-Barr-Virus (EBV) plays an important role as trigger or cofactor for various autoimmune diseases. In a subset of patients with Chronic Fatigue Syndrome (CFS) disease starts with infectious mononucleosis as late primary EBV-infection, whereby altered levels of EBVspecific antibodies can be observed in another subset of patients. Methods: We performed a comprehensive mapping of the IgG response against EBV comparing 50 healthy controls with 92 CFS patients using a microarray platform. Patients with multiple sclerosis (MS), systemic lupus erythematosus (SLE) and cancer-related fatigue served as controls. 3054 overlapping peptides were synthesised as 15-mers from 14 different EBV proteins. Array data was validated by ELISA for selected peptides. Prevalence of EBV serotypes was determined by qPCR from throat washing samples. Results: EBV type 1 infections were found in patients and controls. EBV seroarray profiles between healthy controls and CFS were less divergent than that observed for MS or SLE. We found significantly enhanced IgG responses to several EBNA-6 peptides containing a repeat sequence in CFS patients compared to controls. EBNA-6 peptide IgG responses correlated well with EBNA-6 protein responses. The EBNA-6 repeat region showed sequence homologies to various human proteins. Conclusion: Patients with CFS had a quite similar EBV IgG antibody response pattern as healthy controls. Enhanced IgG reactivity against an EBNA-6 repeat sequence and against EBNA-6 protein is found in CFS patients. Homologous sequences of various human proteins with this EBNA-6 repeat sequence might be potential targets for antigenic mimicry